Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where B. P. C. Koeleman is active.

Publication


Featured researches published by B. P. C. Koeleman.


Neurology | 2005

Lack of association between VEGF polymorphisms and ALS in a Dutch population

P.W.J. van Vught; Nadia A. Sutedja; J. H. Veldink; B. P. C. Koeleman; G. J. Groeneveld; Cisca Wijmenga; B. M.J. Uitdehaag; J.M.B.V. de Jong; Frank Baas; J.H.J. Wokke; L. H. van den Berg

Sequence alterations in the promoter region of the vascular endothelial growth factor (VEGF) gene have been implicated in increasing the risk of developing ALS. VEGF promoter haplotypes were determined in 373 patients with sporadic ALS and 615 matched healthy controls in The Netherlands. No significant association between the previously reported at-risk haplotypes and ALS was found. Pooling our results with the previously studied population still showed a significant association with the AAG haplotype.


Annals of the Rheumatic Diseases | 2010

The TRAF1-C5 region on chromosome 9q33 is associated with multiple autoimmune diseases.

Fina Kurreeman; George N. Goulielmos; Behrooz Z. Alizadeh; Blanca Rueda; Jeanine J. Houwing-Duistermaat; Elena Sánchez; Marianna Bevova; T.R.D.J. Radstake; Madelon C. Vonk; E. Galanakis; N. Ortego; W. Verduyn; Maria Zervou; Bart O. Roep; Bárbara Dema; L. Espino; Elena Urcelay; Dimitrios T. Boumpas; L. H. van den Berg; Cisca Wijmenga; B. P. C. Koeleman; T. W. J. Huizinga; René E. M. Toes; J. Martin

Objectives The TRAF1-C5 locus has recently been identified as a genetic risk factor for rheumatoid arthritis (RA). Since genetic risk factors tend to overlap with several autoimmune diseases, a study was undertaken to investigate whether this region is associated with type 1 diabetes (TID), celiac disease (CD), systemic sclerosis (SSc) and systemic lupus erythematosus (SLE). Methods The most consistently associated SNP, rs10818488, was genotyped in a total of 735 patients with T1D, 1049 with CD, 367 with SSc, 746 with SLE and 3494 ethnically- and geographically-matched healthy individuals. The replication sample set consisted of 99 patients with T1D, 272 with SLE and 482 healthy individuals from Crete. Results A significant association was detected between the rs10818488 A allele and T1D (OR 1.14, p=0.027) and SLE (OR 1.16, p=0.016), which was replicated in 99 patients with T1D, 272 with SLE and 482 controls from Crete (OR 1.64, p=0.002; OR 1.43, p=0.002, respectively). Joint analysis of all patients with T1D (N=961) and all patients with SLE (N=1018) compared with 3976 healthy individuals yielded an allelic common OR of 1.19 (p=0.002) and 1.22 (p=2.6×10−4), respectively. However, combining our dataset with the T1D sample set from the WTCCC resulted in a non-significant association (OR 1.06, p=0.087). In contrast, previously unpublished results from the SLEGEN study showed a significant association of the same allele (OR 1.19, p=0.0038) with an overall effect of 1.22 (p=1.02×10−6) in a total of 1577 patients with SLE and 4215 healthy individuals. Conclusion A significant association was found for the TRAF1-C5 locus in SLE, implying that this region lies in a pathway relevant to multiple autoimmune diseases.


Annals of the Rheumatic Diseases | 2015

A genome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides

Lara Bossini-Castillo; C. de Kovel; Henrik Källberg; R. van 't Slot; Annet Italiaander; M. Coenen; Paul P. Tak; M.D. Posthumus; Cisca Wijmenga; Tom Huizinga; A H M van der Helm-van Mil; G. Stoeken-Rijsbergen; Luis Rodriguez-Rodriguez; Alejandro Balsa; Isidoro González-Álvaro; Miguel A. González-Gay; Gómez-Vaquero C; Barbara Franke; Sita H. Vermeulen; I E van der Horst-Bruinsma; Ben A. C. Dijkmans; G. Wolbink; Roel A. Ophoff; M. T. Maehlen; P.L.C.M. van Riel; Marilyn E. Merriman; L Klareskog; Benedicte A. Lie; Tony R. Merriman; J B A Crusius

Introduction Rheumatoid arthritis (RA) patients can be classified based on presence or absence of anticitrullinated peptide antibodies (ACPA) in their serum. This heterogeneity among patients may reflect important biological differences underlying the disease process. To date, the majority of genetic studies have focused on the ACPA-positive group. Therefore, our goal was to analyse the genetic risk factors that contribute to ACPA-negative RA. Methods We performed a large-scale genome-wide association study (GWAS) in three Caucasian European cohorts comprising 1148 ACPA-negative RA patients and 6008 controls. All patients were screened using the Illumina Human Cyto-12 chip, and controls were genotyped using different genome-wide platforms. Population-independent analyses were carried out by means of logistic regression. Meta-analysis with previously published data was performed as follow-up for selected signals (reaching a total of 1922 ACPA-negative RA patients and 7087 controls). Imputation of classical HLA alleles, amino acid residues and single nucleotide polymorphisms was undertaken. Results The combined analysis of the studied cohorts resulted in identification of a peak of association in the HLA-region and several suggestive non-HLA associations. Meta-analysis with previous reports confirmed the association of the HLA region with this subset and an observed association in the CLYBL locus remained suggestive. The imputation and deep interrogation of the HLA region led to identification of a two amino acid model (HLA-B at position 9 and HLA-DRB1 at position 11) that accounted for the observed genome-wide associations in this region. Conclusions Our study shed light on the influence of the HLA region in ACPA-negative RA and identified a suggestive risk locus for this condition.


Annals of the Rheumatic Diseases | 2012

Genetic variants in IL15 associate with progression of joint destruction in rheumatoid arthritis: a multicohort study

Rachel Knevel; A. Krabben; Elisabeth Brouwer; Marcel D. Posthumus; Anthony G. Wilson; Elisabet Lindqvist; Tore Saxne; D. P. C. de Rooy; Nina A. Daha; M. P. M. van der Linden; G. Stoeken; L. van Toorn; B. P. C. Koeleman; Roula Tsonaka; A. Zhernakoza; Jeanine J. Houwing-Duistermaat; René E. M. Toes; T. W. J. Huizinga; A H M van der Helm-van Mil

Background Interleukin (IL)-15 levels are increased in serum, synovium and bone marrow of patients with rheumatoid arthritis (RA). IL-15 influences both the innate and the adaptive immune response; its major role is activation and proliferation of T cells. There are also emerging data that IL-15 affects osteoclastogenesis. The authors investigated the association of genetic variants in IL15 with the rate of joint destruction in RA. Method 1418 patients with 4885 x-ray sets of both hands and feet of four independent data sets were studied. First, explorative analyses were performed on 600 patients with early RA enrolled in the Leiden Early Arthritis Clinic. Twenty-five single-nucleotide polymorphisms (SNPs) tagging IL-15 were tested. Second, SNPs with significant associations in the explorative phase were genotyped in data sets from Groningen, Sheffield and Lund. In each data set, the relative increase of the progression rate per year in the presence of a genotype was assessed. Subsequently, data were summarised in an inverse weighting meta-analysis. Results Five SNPs were significantly associated with rate of joint destruction in phase 1 and typed in the other data sets. Patients homozygous for rs7667746, rs7665842, rs2322182, rs6821171 and rs4371699 had respectively 0.94-, 1.04-, 1.09-, 1.09- and 1.09-fold rate of joint destruction compared to other patients (p=4.0×10−6, p=3.8×10−4, p=5.0×10−3, p=5.0×10−3 and p=9.4×10−3). Discussion Independent replication was not obtained, possibly due to insufficient power. Meta-analyses of all data sets combined resulted in significant results for four SNPs (rs7667746, p<0.001; rs7665842, p<0.001; rs4371699, p=0.01; rs6821171, p=0.01). These SNPs were also significant after correction for multiple testing. Conclusion Genetic variants in IL-15 are associated with progression of joint destruction in RA.


Genes and Immunity | 2004

Defining the contribution of the HLA region to cis DQ2-positive coeliac disease patients

M.J. van Belzen; B. P. C. Koeleman; J B A Crusius; Jos W. R. Meijer; Alfons Bardoel; Peter L. Pearson; Lodewijk A. Sandkuijl; Roderick H. J. Houwen; Cisca Wijmenga

The major genetic susceptibility to coeliac disease is contributed by the human leukocyte antigen (HLA) region. The primary association is with the HLA-DQ2 molecule, encoded by the DQA1*05 and DQB1*02 alleles, which is expressed by over 90% of patients. The aim of our study was to perform an extensive scan of the entire HLA region to determine whether there is evidence for the presence of additional HLA susceptibility genes for coeliac disease in the Dutch population, acting independently of DQ2. In all, 16 microsatellite markers and the DQA1 and DQB1 genes were genotyped in simplex cis DQ2-positive coeliac disease families and cis DQ2-positive control families. Allele frequencies of markers on phase-known DQ2-positive haplotypes transmitted to patients were compared to a combined group of DQ2-positive nontransmitted and control haplotypes, thereby controlling for the DQ2 contribution. No significant differences at any of the marker loci were detected, suggesting that DQ2 is the major HLA risk factor for coeliac disease. Individuals homozygous for DQ2 or heterozygous for DQA1*05-DQB1*02/DQA1*0201-DQB1*02 were found to be at five-fold increased risk for development of coeliac disease (P<10−8). This risk seems to be conferred by the presence of a second DQB1*02 allele next to one DQA1*05-DQB1*02 haplotype, independently of the second DQA1 allele.


Neurogenetics | 2013

Clinical and genetic aspects of PCDH19-related epilepsy syndromes and the possible role of PCDH19 mutations in males with autism spectrum disorders

J. J. T. van Harssel; Sarah Weckhuysen; M.J.A. van Kempen; Katia Hardies; Nienke E. Verbeek; C. de Kovel; Wb Gunning; E van Daalen; M.V. de Jonge; A. Jansen; R. Vermeulen; W.F.M. Arts; H. Verhelst; A. Fogarasi; J. F. de Rijk-van Andel; A. Kelemen; Dick Lindhout; P. De Jonghe; B. P. C. Koeleman; Arvid Suls; Eva H. Brilstra

Epilepsy and mental retardation limited to females (EFMR), caused by PCDH19 mutations, has a variable clinical expression that needs further exploration. Onset of epilepsy may be provoked by fever and can resemble Dravet syndrome. Furthermore, transmitting males have no seizures, but are reported to have rigid personalities suggesting possible autism spectrum disorders (ASD). Therefore, this study aimed to determine the phenotypic spectrum associated with PCDH19 mutations in Dravet-like and EFMR female patients and in males with ASD. We screened 120 females suffering from Dravet-like epilepsy, 136 females with EFMR features and 20 males with ASD. Phenotypes and genotypes of the PCDH19 mutation carriers were compared with those of 125 females with EFMR reported in the literature. We report 15 additional patients with a PCDH19 mutation. Review of clinical data of all reported patients showed that the clinical picture of EFMR is heterogeneous, but epilepsy onset in infancy, fever sensitivity and occurrence of seizures in clusters are key features. Seizures remit in the majority of patients during teenage years. Intellectual disability and behavioural disturbances are common. Fifty percent of all mutations are missense mutations, located in the extracellular domains only. Truncating mutations have been identified in all protein domains. One ASD proband carried one missense mutation predicted to have a deleterious effect, suggesting that ASD in males can be associated with PCDH19 mutations.


Epilepsy Research | 2010

Whole-genome linkage scan for epilepsy-related photosensitivity: a mega-analysis.

C. G. F. de Kovel; Dalila Pinto; Ulrike Tauer; S. Lorenz; Hiltrud Muhle; Costin Leu; Bernd A. Neubauer; Anne Hempelmann; Petra M.C. Callenbach; Ingrid E. Scheffer; Samuel F. Berkovic; Gabrielle Rudolf; Pasquale Striano; Auli Siren; Betül Baykan; Thomas Sander; Dick Lindhout; D. G Kasteleijn Nolst Trenité; Ulrich Stephani; B. P. C. Koeleman

Photoparoxysmal response (PPR) is considered to be a risk factor for idiopathic generalised epilepsy (IGE) and it has a strong genetic basis. Two genome-wide linkage studies have been published before and they identified loci for PPR at 6p21, 7q32, 13q13, 13q31 and 16p13. Here we combine these studies, augmented with additional families, in a mega-analysis of 100 families. Non-parametric linkage analysis identified three suggestive peaks for photosensitivity, two of which are novel (5q35.3 and 8q21.13) and one has been found before (16p13.3). We found no evidence for linkage at four previously detected loci (6p21, 7q32, 13q13 and 13q31). Our results suggest that the different family data sets are not linked to a shared locus. Detailed analysis showed that the peak at 16p13 was mainly supported by a single subset of families, while the peaks at 5q35 and 8q21 had weak support from multiple subsets. Family studies clearly support the role of PPR as a risk factor for IGE. This mega-analysis shows that distinct loci seem to be linked to subsets of PPR-positive families that may differ in subtle clinical phenotypes or geographic origin. Further linkage studies of PPR should therefore include in-depth phenotyping to make appropriate subsets and increase genetic homogeneity.


Genes and Immunity | 2002

Genetic determinants of rheumatoid arthritis: the inducible nitric oxide synthase (NOS2) gene promoter polymorphism

Maria J. Pascual; M. A. López-Nevot; R Cáliz; B. P. C. Koeleman; Alejandro Balsa; Dora Pascual-Salcedo; J. Martin

An association study and a linkage analysis were carried out in parallel in order to investigate the association of the inducible nitric oxide synthase (NOS2) gene promoter polymorphism with rheumatoid arthritis (RA) predisposition and/or outcome including a −954G-C mutation, a di-allelic (TAAA)n marker and the highly polymorphic (CCTTT). The −954G-C point mutation occurred non-polymorphic and the di-allelic (TAAA)n marker was not associated with RA predisposition. The (CCTTT)nlocus showed a trend for RA association in the case-control study, however, stratification data by Class II status did not yield significant effect and overall, the family study showed no significant association nor linkage for any of the markers under study using TDT and non-parametric linkage respectively. Finally, no influence was detected regarding any of the clinical parameters tested. After evaluating for the first time the influence of NOS2 promoter polymorphism in RA, it seems to have no major effect on disease susceptibility and/or outcome.


Diabetologia | 2008

Study of the association between the CAPSL-IL7R locus and type 1 diabetes

Jose Luis Santiago; Behrooz Z. Alizadeh; A Martínez; L. Espino; H de la Calle; Miguel Fernández-Arquero; M. A. Figueredo; E. G. de la Concha; Bart O. Roep; B. P. C. Koeleman; Elena Urcelay

Aims/hypothesisIn the past few years, several genes outside the MHC region have been described as new susceptibility genetic factors to type 1 diabetes. An association between CAPSL-rs1445898 and type 1 diabetes was reported in a large white population and corroborated in a genome-wide analysis, which also found an association with IL7R, which is located adjacent to CAPSL. The aim of this study was to replicate the aforementioned associations in independent cohorts.MethodsWe analysed two CAPSL (rs1010601 and rs1445898) and three IL7R (rs6897932, rs987106 and rs3194051) polymorphisms. All these single nucleotide polymorphisms (SNPs) were genotyped using TaqMan minor groove binder chemistry in 301 unrelated Spanish type 1 diabetes patients and 646 healthy controls. Additionally, the associated CAPSL SNP rs1445898 was genotyped in a Dutch cohort consisting of 429 type 1 diabetes patients and 720 healthy controls.ResultsThe homozygous mutant genotype of the CAPSL SNP rs1445898 showed a trend towards a protective effect in the overall Spanish cohort (OR [95% CI] 0.70 [0.44–1.09]; p = 0.09) and in the Dutch cohort (OR [95% CI] 0.74 [0.51–1.05]; p = 0.09). Pooling of both cohorts was performed, yielding a statistically significant difference (Mantel–Haenszel OR 0.71; p = 0.005). This protective effect was significantly different in early-onset vs late-onset Spanish patients (OR [95% CI] 0.26 [0.10–0.65]; p = 0.001). Similarly, in the early-onset subgroup, the homozygous mutant genotype of the IL7R SNP rs6897932 showed a similar protective effect (OR [95% CI] 0.18 [0.02–0.94]; p = 0.02).Conclusions/interpretationIn summary, we describe an independent replication of the association between the CAPSL-IL7R locus and type 1 diabetes, especially for early-onset type 1 diabetes patients.


Journal of Translational Medicine | 2010

Identification of novel genetic markers associated with the clinical phenotypes of systemic sclerosis through a genome wide association strategy

Olga Y. Gorlova; Jose-Ezequiel Martin; Blanca Rueda; B. P. C. Koeleman; Jun Ying; María Teruel; Lina Marcela Diaz-Gallo; J. Broen; Madelon C. Vonk; Carmen P. Simeon; Behrooz Z. Alizadeh; M. Coenen; Alexandre E. Voskuyl; Annemie J. Schuerwegh; Plcm van Riel; Marie Vanthuyne; R. van 't Slot; Annet Italiaander; Roel A. Ophoff; Nicolas Hunzelmann; Vicente Fonollosa; Norberto Ortego-Centeno; Miguel A. González-Gay; Francisco J. García-Hernández; María Francisca González-Escribano; Paolo Airò; J M van Laar; Jane Worthington; Roger Hesselstrand; Vanessa Smith

Identification of novel genetic markers associated with the clinical phenotypes of systemic sclerosis through a genome wide association strategy O Gorlova, J M Martin, B Rueda, BPC Koeleman, J Ying, M Teruel, L M Diaz-Gallo, J C Broen, M C Vonk, C P Simeon, B Z Alizadeh, MJH Coenen, A E Voskuyl, A J Schuerwegh, PLCM van Riel, M Vanthuyne, R van ‘t Slot, A Italiaander, R A Ophoff, N Hunzelmann, V Fonollosa, N Ortego-Centeno, M A González-Gay, F J García-Hernández, M F González-Escribano, P Airo, J van Laar, J Worthington, R Hesselstrand, V Smith, F De Keyser, F Houssiau, M M Chee, R Madhok, P Shiels, R Westhovens, A Kreuter, E de Baere, T Witte, L Padyukov, A Nordin, R Scorza, C Lunardi, B A Lie, A M Hoffmann-Vold, P García de la Peña, P Carreira, J Varga, M Hinchcliff, A T Lee, P Gourh, C I Amos, G Riemekasten, A Herrick, L Beretta, C Fonseca, C P Denton, P K Gregersen, S Agarwal, S Assassi, F K Tan, F C Arnett, TRDJ Radstake, M D Mayes, J Martin

Collaboration


Dive into the B. P. C. Koeleman's collaboration.

Top Co-Authors

Avatar

Bart O. Roep

Beckman Research Institute

View shared research outputs
Top Co-Authors

Avatar

J. Martin

Spanish National Research Council

View shared research outputs
Top Co-Authors

Avatar

Behrooz Z. Alizadeh

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Cisca Wijmenga

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Madelon C. Vonk

Radboud University Nijmegen

View shared research outputs
Top Co-Authors

Avatar

Blanca Rueda

Spanish National Research Council

View shared research outputs
Top Co-Authors

Avatar

A H M van der Helm-van Mil

Leiden University Medical Center

View shared research outputs
Top Co-Authors

Avatar

M. Coenen

Radboud University Nijmegen

View shared research outputs
Top Co-Authors

Avatar

René E. M. Toes

Leiden University Medical Center

View shared research outputs
Top Co-Authors

Avatar

T. W. J. Huizinga

Leiden University Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge